Tridek-One SAS, a French biotech startup specializing in the research and development of CD31 agonists to restore immune balance, has closed a new €16 million ($16.1 million) funding round.
The financing was led by Swiss company Pureos Bioventures with the participation of new investors Bpifrance and Bioqube Ventures, as well as historical investors AdBio partners and Advent Life Sciences.
The funds will be used primarily to identify development candidates against autoimmune diseases, to conduct studies enabling IND and to further strengthen the organization. The company previously raised €3 million ($3 million) in a first round in 2019 involving partners AdBio and Advent Life Sciences.
Founded in 2018 by Giuseppina Caligiuri and Antonino Nicoletti, researchers from INSERM Unit 1148 in Paris, France, with the support of historical investor partners AdBio, Tridek-One is developing a new CD31 agonist approach to modulate immune activation for the treatment autoimmune diseases.
Following the fundraising, Klaus Breiner from Pureos Bioventures and Benoit Barteau from Bpifrance join the company’s board of directors. Erik van den Berg, CEO of AM-Pharma, joins as independent chairman of the board.
“It is a pleasure to join as Chairman as the company builds a great team, with a professional syndicate of international investors engaging in decades of research by the team of Dr Giuseppina Caligiuri and Pr Antonino Nicoletti “said Erik van den Berg, Chairman of the Board of Tridek-One.
“There is still a significant unmet medical need in many autoimmune diseases. Agonizing immune inhibitory receptors like CD31 have the potential to rebalance the immune system without being more broadly immunosuppressive. We are excited to continue translating this concept with Tridek-One through its discovery and preclinical stages,” added Klaus Breiner, Managing Partner at Pureos Bioventures.
“Being supported by investors who believe in our project is a great opportunity. This will allow us to accelerate our work to identify and develop first-in-class immune checkpoint agonists capable of controlling serious inflammatory diseases,” said the founders of Tridek-One.